Monopar Therapeutics (NASDAQ: MNPR) — Perfil da empresa, notícias e dados financeiros
Monopar Therapeutics develops innovative cancer therapeutics, focusing on enhancing treatment outcomes for cancer patients.
Monopar Therapeutics
Monopar Therapeutics (NASDAQ:MNPR) focuses on developing innovative therapeutics aimed at improving clinical outcomes in cancer patients. Its operations span from early-stage discovery to advanced clinical trials, with projects targeting various aspects of cancer treatment, including drug development for cachexia in advanced cancer patients and novel therapies to enhance the effectiveness of current cancer treatments. Objectives center on addressing unmet medical needs in oncology, striving to bring transformative treatments to market. With a dedicated team and a strategic approach to oncology research, Monopar Therapeutics is committed to achieving milestones that could significantly impact cancer care.
Resumo
Operações
Produtos e/ou serviços de Monopar Therapeutics
- Validive (clonidine MBT) for the prevention of severe oral mucositis in cancer patients.
- Camsirubicin for the treatment of advanced soft tissue sarcoma, targeting cancer without damaging the heart.
- MNPR-101 conjugated radioimmunotherapies for advanced cancers, with a focus on targeting uPAR to deliver therapy directly to tumors.
- MNPR-201, a preclinical development program aimed at developing new therapeutics for severe diseases, including cancer.
- A partnership for developing a COVID-19 therapeutic, focusing on mitigating life-threatening side effects.
- Development of a proprietary technology platform to enhance the delivery and efficacy of their therapeutics in targeted disease areas.
equipe executiva do Monopar Therapeutics
- Christopher M. StarrCo-Founder & Independent Executive Chairman of the Board
- Chandler D. RobinsonCo-Founder, CEO, President & Director
- Quan Anh VuCFO, Principal accounting officer, Principal financial officer, Secretary & Treasurer
- Andrew J. CittadineChief Operating Officer
- Patrice P. RiouxActing Chief Medical Officer
- Susan RodriguezChief Commercial & Strategy Officer
- Jeffrey D. KentExecutive Vice President of Head of Medical Affairs
Principais indicadores financeiros
Resultados divulgados pela Monopar Therapeutics, em USD.
- Cap. de mercado
- 492,6 mi
- Receita (TTM)
- 0
- P/L
- —
- LPA (diluído, TTM)
- -2.2
- Dividend yield
- —
- Margem de lucro
- 0.0%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 0 | -16,7 mi | -13,7 mi | |
| 0 | -16,2 mi | -15,6 mi | |
| 0 | -8,8 mi | -8,4 mi | |
| 0 | -10,5 mi | -10,5 mi |